유아 혈관종에서 저용량 Propranolol의 사용 적절성 평가 = Drug Use Evaluation of Low-dose Propranolol on Infantile Hemangioma

다국어 초록 (Multilingual Abstract)

Infantile hemangiomas (IH) are the most common benign tumor during childhood.
The majority are self-resolving, however, 10% of patients require treatment. Researches on theefficacy of propranolol for IH have been reported outside of Korea since 2008. This study evaluateda low-dose propranolol use on IH based on its clinical efficacy and adverse event profiles.
Total of 59 children, 3-year-old or younger, diagnosed IH and took propranolol as a maintenancedosage of 2 mg/kg/day between November 2009 and July 2011, were culled from SeoulNational University Children’s Hospital using electrolyte medical records retrospectively. Forcomparison, clinical photos were taken before, during and after treatment.
IH was predominantly presented in female (Male: Female=1:2.5), 39% of which occurred and wasdistinguished at birth (n=23). For the remains (n=36), 69% of children (n=25) occurred within amonth. Location of the IH was as follows: face and neck (n=44), trunk (n=4), the limbs (n=6), multiples (n=5), respectively. Mean age of treatment initiation was 5-month-old (range 1.3-16)and the total duration of treatment was an average of 8 months (range 2.3-22). 22% of patientsshowed a rebound growth when the medication was discontinued and restarted propranolol,receiving relatively shorter courses; a mean of 4 months (range 1 week - 11 months). Based on theinitial diagnosis, more than 50% of the reduction in the size of lesion was exhibited at 48patients, followed by four with less reduction and no changes in seven. Total 59% of patients(n=36) displayed improvement within a month such as a regression in size, softening in the lesionand faded in color. 22 patients experienced minor but reportable side effects to propranolol,including rash (n=8), gastro-esophageal reflux (n=7), hypotension (n=3), somnolence (n=2), andothers (respiratory distress, n=1, hypothermia, n=1), respectively.
In this study, the clinical efficacy of low-dose propranolol use on IH was confirmed. Due to thelimited data from Seoul National University Children’s Hospital, prospective studies with morepatients are needed and the guideline for duration and dosage of propranolol should be furtherelaborated.

참고문헌 (Reference)

1 Denoyelle F., "Role of propranolol in the therapeutic strategy of infantile larygotrachealhemangioma" 73 : 1168-1172, 2009

2 Leslie P. Lawley, "Propranolol treatment for hemangioma of infancy: risks and recommenda-tions" 26 : 610-614, 2009

3 Zimmermann A.P, "Propranolol therapy for infantile haemangiomas:review of the literature" 74 : 338-342, 2010

4 Sans V., "Propranolol for severe infantile hemangiomas: follow-up report" 124 : 423-431, 2009

5 Leaute-Labreze C., "Propranolol for severe hemangiomas of infancy" 358 : 2649-2651, 2008

6 Buckmiller L.M., "Propranolol for infantile henmangiomas:early experience at a tertiary vascular anomalies center" 120 : 676-681, 2010

7 E. Starkey, "Propranolol for infantile haemangiomas: a review" 2011

8 Manunza F., "Propranolol for complicated infantile haemangiomas: a case series of 30 infants" 162 : 466-468, 2010

9 Buckmiller L., "Propranolol for airway hemangiomas: case report of novel treatment" 73 : 2051-2054, 2009

10 W.J.M. Holmes, "Propranolol as first-line treatment for rapidly proliferating infantile haemangiomas" 64 : 445-451, 2010

11 Carol K. Taketomo, "Pediatric Dosage Handbook" Lexi-Comp 1175-1178,

12 Swee T. Tan, "Low-dose propranolol for infantile haemangioma" 64 : 292-300, 2010

13 Laccarino G, "Ischemic neoangiogenesis enhanced by beta2-adrenergic receptor over expression:a novel role of the endothelial adrenergic system" 97 (97): 1182-1189, 2005

14 Drolet B.A., "Infantile hemangiomas: an emerging health issue linked to an increased rate of low birth weight infants" 7 : 712-715, 2008

15 Frieden I.J., "Guidelines of care for hemangiomas of infancy" 37 : 631-637, 1997